In the Claims:

1. (Canceled)

2. (Canceled)

3. (Canceled)

4. (Canceled)

5. (Canceled)

6. (Canceled)

7. (Currently Amended) A method for producing a plurality of crystalline ~~of micronizing~~ (E) – 4 – [2 – [2 – [N – acetyl – N – (4 – methoxybenzenesulfonyl) amino]phenyl]-ethenyl]pyridine 1-oxide particles with a mean particle diameter of from 1 μm to about 25 μm with particles larger than 50 μm constituting a fraction of not more than 2% of a total number of particles, ~~compounds~~ comprising the step of ~~pulverizing~~ micronizing the crystalline compound with an open-circuit pulverizing type mill.

8. (Previously Presented) The micronizing method of Claim 7 wherein said open-circuit pulverizing type mill is either a high-speed rotary impact mill or a pneumatic mill.

9. (Canceled)

10. (Canceled)

11. (Withdrawn) A chemical composition comprising a plurality of crystalline (E) – 4 – [2 – [2 – [N – acetyl – N – (4 – methoxybenzenesulfonyl)amino]phenyl]ethenyl] – pyridine 1 – oxide

particles with a mean particle diameter of from 1 μm to about 25 μm with particles larger than 50 μm constituting a fraction of not more than 2% of a total number of particles.

12. (Withdrawn) A pharmaceutical composition comprising a therapeutically effective amount of the plurality of crystalline (E) – 4 – [2 – [2 – [N – acetyl – N – (4 – methoxybenzenesulfonyl)amino]phenyl]ethenyl] – pyridine 1 – oxide particles of claim 11 as an active ingredient.

13. (Withdrawn) An anticancer drug comprising a therapeutically effective amount of the plurality of crystalline (E) – 4 – [2 – [2 – [N – acetyl – N – (4 – methoxybenzenesulfonyl)amino]phenyl]ethenyl] – pyridine 1 – oxide particles of claim 11 as an active ingredient.